Previous 10 | Next 10 |
FinancialBuzz.com News Commentary New York, NY (11/25/2020) – As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data. Dr. Anthony Fauci, the National Institute of Allergy and Infectious Disea...
Vyrologix™ (leronlimab) has successfully replicated the CCR5 deficient phenotype in a pre-clinical animal study, and will now initiate HIV cure-focused clinical studies in collaboration with amfAR VANCOUVER, Washington, Nov. 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn...
CytoDyn (CYDY) has reached enrollment of 293 patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms, thereby meeting requested criteria for a second interim efficacy analysis by the Data Safety Monitoring Committee ((DSMC)).The company expects to enroll the remai...
Concurrently, CytoDyn is w orking d iligently with the FDA to initiate its Phase 2 COVID-19 Long Hauler T rial , with m ore than 100 volu n teers wanting to enroll VANCOUVER, Washington, Nov. 23, 2020 (GLOBE N...
Rapid Enrollment Expected , As Many People Have Already Volunteered VANCOUVER, Washington, Nov. 17, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company de...
Health Canada has cleared CytoDyn (CYDY) to file its Biologics License Application ((BLA)) for leronlimab as a combination therapy for multi-drug resistance HIV patients in Canada. The BLA filing includes a treatment regimen of one injection per week of 350 mg of leronlimab, as contrasted to ...
Vyrologix is the proprietary name for leronli ma b VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...
VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
CytoDyn (CYDY) has completed an additional non-dilutive convertible debt offering with an institutional investor, and provides $25M of immediately available capital. The note has a two-year maturity, bears annual interest rate of 10%. Conversion price for the note is $10/share.The company say...
VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...